RxDoctor Payments Data

Timothy Lestingi, MD

Hematology & Oncology · Park Ridge, ILNPI 1114986411

Payments from drug & device makers

$106,982in general payments, 2019–2025

Across 19 payments — averaging $5630.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$98K
  • AstraZeneca$8K
  • Telix Pharmaceuticals$149
  • AbbVie$126
  • Pharmacyclics LLC, An Abbvie Company$101
  • Gilead$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$62597%
  • Education$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,982 in reported general payments places this provider in the 70th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$118,495
Medicare patients
357
Services billed
1,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate19$429,395
LenvimaLenvatinib Mesylate16$371,352
InlytaAxitinib15$306,993
RubracaRucaparib Camsylate15$239,490
XtandiEnzalutamide16$238,736
Abiraterone Acetate96$114,507
EliquisApixaban54$37,796
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$1,143
Prednisone113$820
Anastrozole40$800
Dexamethasone34$591
Prochlorperazine Maleate63$513
Levothyroxine Sodium60$432
Megestrol Acetate13$415
Bicalutamide19$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$14$344,78869 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Park Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →